The Impact of Korean Medicine Treatment on the Incidence of Parkinson’s Disease in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study in South Korea
Open Access
- 28 July 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2422
Abstract
We aimed to investigate the association between Korean medicine (KM) treatment and the risk of Parkinson’s Disease (PD) in patients with inflammatory bowel disease (IBD) in South Korea. This study analyzed data from the National Health Insurance Service-Senior cohort in South Korea. The 1816 IBD patients enrolled in the analysis comprised 411 who received only conventional treatment (monotherapy group) and 1405 who received both conventional and KM treatments (integrative therapy group). The risk of PD in patients with IBD was significantly lower in the integrative therapy group than in the monotherapy group after adjusting for confounding variables (adjusted hazard ratio (HR), 0.56; 95% confidence interval (CI) = 0.34–0.92). In the mild Charlson Comorbidity Index (CCI) group, the risk of PD in patients with IBD in the integrative therapy group was 0.39 times lower (adjusted HR, 95% CI = 0.20–0.77) than that in the monotherapy group. However, there was no significant difference in the risk of PD in patients with IBD between the integrative therapy and monotherapy groups among individuals with severe CCI (adjusted HR, 0.90; 95% CI = 0.41−1.96). IBD patients are at a decreased risk of PD when they receive integrative therapy. KM treatment may prevent PD in IBD patients.Keywords
Funding Information
- Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A1B03031688)
This publication has 37 references indexed in Scilit:
- The microbiota in inflammatory bowel diseaseJournal of Gastroenterology, 2015
- Acupuncture and Moxibustion for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsEvidence-Based Complementary and Alternative Medicine, 2013
- Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s Disease?Frontiers in Cellular Neuroscience, 2013
- Pathological correlates of gastrointestinal dysfunction in Parkinson's diseaseNeurobiology of Disease, 2012
- Surveillance Bias in Outcomes ReportingJAMA, 2011
- Medical Service Utilization with OsteoporosisEndocrinology and Metabolism, 2010
- Short communication Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's diseaseActa Neurologica Scandinavica, 2009
- Surveillance Bias and Deep Vein Thrombosis in the National Trauma Data Bank: The More We Look, The More We FindJournal of Trauma: Injury, Infection & Critical Care, 2008
- The Neuroimmune Hypothesis in Parkinson's DiseaseReviews in the Neurosciences, 1997
- Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patientsNeuroscience Letters, 1995